• Ongoing Phase 1b human challenge study with oral, direct-acting protease inhibitor is designed to demonstrate proof-of-concept as a preventive and a treatment
  • Fully enrolled first cohort is assessing the infectivity of the human challenge inoculum
  • There are no approved treatments or vaccines for norovirus, the leading cause of acute gastroenteritis across all age groups and geographies with a $60 billion annual economic burden
  • FDA Fast Track designation granted for CDI-988 underscores the lack of approved therapies and seriousness of norovirus infection

BOTHELL, Wash., April 30, 2026 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ:COCP) ("Cocrystal" or the "Company") announces that the mechanism of action and clinical advancement of its first oral protease inhibitor CDI-988 were featured today in an oral presentation at the 39th International Conference on Antiviral Research (ICAR 2026) in Prague, Czech Republic. The presentation, titled "First Oral Direct-Acting Antiviral CDI-988 for Norovirus Infection Prevention and Treatment: Novel Mechanism of Action and Phase 1 Study Results," was delivered by Sam Lee, Ph.D., President and co-CEO of Cocrystal.